2 publications
-
Published Subscription Review Article
SGLT2 Inhibitors in Heart Failure and Chronic Kidney Disease: Expanding Therapeutic Horizons beyond Glycemic ControlBy Hamsa Priya M, Bharath B, Darshan G
Abstract: Heart failure (HF) and chronic kidney disease (CKD) are closely related clinical diseases that significantly increase morbidity and death worldwide. The co-occurrence of both conditions is frequently referred to as the "cardio-renal syndrome," in which the failure of one organ hastens the decline of the other. The original purpose of sodium–glucose cotransporter-2 (SGLT2) inhibitors was to treat type 2 diabetic mellitus (T2DM) by reducing blood sugar levels. Nevertheless, new data …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 16, Issue 2, 2026 Read article →
-
Published Subscription Review Article
GLP-1 Receptor Agonists: A Dual Therapeutic Strategy for the Management of Type 2 Diabetes Mellitus and ObesityBy Darshan G, Hamsa Priya M, Bharath B
Abstract: For the treatment of obesity and type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a revolutionary class of pharmaceutical drugs. These drugs were first created as glucose-lowering treatments, but they have now shown other advantages, such as notable weight loss, better cardiovascular results, and general metabolic control. The objective of this narrative review is to assess the pharmacological mechanisms, clinical efficacy, safety profile, and therapeutic …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 16, Issue 1, 2026 · pp. 69–75 Read article →